Melanotan I: A Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that has been examined extensively in melanocortin-pathway research. All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. This overview summarizes how researchers describe the compound, what published studies have explored, and the limitations that frame current understanding.
What Melanotan I Is
Melanotan I is a linear 13-amino-acid peptide closely related to the clinically studied agent afamelanotide. It is structurally derived from alpha-MSH, an endogenous peptide that signals through melanocortin receptors. In the research literature it is characterized as a melanocortin receptor agonist with greater metabolic stability than native alpha-MSH, which is why it became a frequent subject of laboratory study. References to the compound in this article reflect how it is described in published peer-reviewed work, not any intended application.
Mechanism and What Research Explores
The melanocortin system comprises five receptor subtypes (MC1R through MC5R) with roles studied in pigmentation, energy balance, and inflammation. In published research, Melanotan I and the related agent afamelanotide are described as acting on the melanocortin 1 receptor (MC1R) expressed on melanocytes. Studies have examined how MC1R activation relates to eumelanin synthesis, which is the central mechanistic question researchers associate with this peptide class. Investigators study the receptor-binding behavior, signaling cascades, and downstream pigmentation pathways in cell and tissue models to understand structure-activity relationships across melanocortin analogues.
Research Stage and Limitations
The most rigorously documented work in this peptide family centers on afamelanotide, which has been the subject of multicenter randomized controlled trials in the context of a rare photodermatosis. Melanotan I itself, as offered for laboratory study, has a far thinner evidence base and should be regarded as an investigational research reagent rather than a characterized therapeutic. Important limitations researchers note include differences between the research-grade peptide and pharmaceutical formulations, variability in published methodology, and the fact that much non-clinical data comes from in vitro or animal models that do not translate directly. Community discussion of this compound exists online, but such material consists of unverified anecdotal reports, not controlled findings, and BioRegen does not make or endorse any claims based on them.
Handling and Laboratory Notes
Lyophilized research peptides are generally described in the literature as requiring cold storage and protection from light and moisture, with reconstitution using an appropriate diluent under controlled conditions. For general background on preparing lyophilized material in a laboratory setting, see our overview on how to reconstitute peptides. These notes are educational descriptions of standard laboratory practice and are not instructions for any use in humans or animals.
Frequently Asked Questions
How does Melanotan I differ from Melanotan II?
In the research literature the two are distinct peptides: Melanotan I is a linear alpha-MSH analogue closely related to afamelanotide and described as relatively MC1R-selective, while Melanotan II is a cyclic peptide reported to act across a broader range of melanocortin receptors. Researchers study them as separate compounds with different receptor profiles.
Is Melanotan I approved for any use?
No compound referenced here is approved for human or veterinary use. The closely related agent afamelanotide has been investigated in regulated clinical trials, but research-grade Melanotan I supplied for laboratory work is intended only for in vitro and educational research.
Where can I compare related research compounds?
Our research finder lets laboratories browse and compare melanocortin and other peptide reagents by their documented research characteristics.
Selected Research References
- Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. https://doi.org/10.1056/NEJMoa1411481
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. J Drugs Dermatol. https://doi.org/10.36849/JDD.5526
Reference metadata sourced via PubMed.
Continue Your Research
For deeper background on study design and reagent selection, explore the BioRegen research guide, and use code RESEARCH10 for 10% off your first order. You can also browse related melanocortin and research peptides in our research catalog category.
This article is provided strictly for laboratory and educational research purposes. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice. BioRegen does not endorse any claim regarding the use of these compounds in humans or animals.